Case Summary:

“[Client] is an outstanding researcher in the field of biomedical sciences, and his work in the U.S. deserves to continue …. Through his educational and professional experiences, [client] has cultivated an unmatched level of expertise in next-generation sequencing, fungal genetics, bioinformatics, and molecular biology.”

The above excerpt is taken from one of the four recommendation letters our client has received from fellow experts in his field. Hailing from China, our client has completed his Ph.D. in integrative molecular and biomedical sciences. Currently employed as a postdoctoral researcher in the field of biomedical sciences, he approached us to acquire his alien of extraordinary ability (EB1-A) petition approval.

A petition for the first preference category of individuals with extraordinary ability, (“EB1-A”), unlike the employment-based immigration visa under the second preference (“EB-2”) at least requires the following:

• Evidence of original contributions, usually through publication, of major significance in the foreign national’s field of science, scholastic, artistic, or athletic.
• No specific job offer/labor certification is required for a foreign person as long as he/she is entering the United States to continue work in the field in which he/she has an extraordinary ability, therefore self-petition is allowed.
• Performance in a significant role for organizations or establishments that have a distinguished reputation.
• Receipt of a higher salary or remuneration than is usual in the field.
• Other comparable evidence if the above types of evidence do not readily apply to the foreign national’s occupation.

Therefore, we included the following key attributes from his academic and professional records in his petition packet to make a strong case in his favor:

• He is particularly well-known for his contributions to the study of the effect of codon usage on translation speed and the structure and function of proteins.
• His biomedical engineering research addresses some of our nation’s and the world’s most pressing issues, including the development of transformative biomedical technologies such as gene therapy and mRNA vaccines.
• His research has resulted in 8 peer-reviewed scientific articles, being cited 510 times in at least 39 countries.
• He has conducted at least 28 reviews for at least 6 journals.
• His study has received funding from the National Institutes of Health, the Welch Foundation, and the Cancer Prevention and Research Institute of Texas.

Consequently, our client’s research contributes to developing novel therapeutic approaches for diseases like cancer.

Thus he achieved his EB1-A (Alien of Extraordinary Ability) approval in just 14 days (thanks to premium processing). We are very pleased to be part of his journey and wish him all the best in his future endeavors.